About Genovant
Evidence AI that a biostatistician, an epidemiologist and a QA reviewer can all check.
We are building one compliance-first AI foundation for the drug and device lifecycle, so the teams that design, run and pay for trials work from the same evidence.
Most AI in this space is fast. Very little of it is checkable.
A top-10 pharma company can run more than seventy AI vendors across protocol authoring, real-world evidence, health economics, safety and regulatory work. None of them share a data spine, so each team rebuilds the same assumptions and the numbers rarely reconcile.
Genovant starts from the other end: every claim cited to its source, every number computed by a named tool, every decision recorded. And because most trial data still represents Western patients, we are building for diverse global populations from the start.
Seven customer segments, with a primary focus on R&D-intensive operators.
The same foundation and compliance shell, with a different lens on the lifecycle for each.
- PrimaryPharmaTrial-sponsor scale, molecule to market
- PrimaryBiotechCapital-efficient path to partnering
- PrimaryCROWin bids competitors can’t quote on
- PrimaryCDMOPredict deviations before the batch starts
- AdjacentMedtech & devicesFrom single-market launch to global access
- SecondaryHospitalsDecision support and trial-recruitment uplift
- SecondaryPayers & insurersOutcomes-based contracts and risk adjustment
Request a showcase
Tell us about the question you’d like to see answered. We’ll come back within two working days to arrange a 45-minute session on public and synthetic data.
Please don’t include patient information or confidential study data in this form.